Upload Image (Max 20MB per Image)
The European Commission (EC) has granted marketing authorization to Pfizer's INLYTA (axitinib) oral therapy, designed to treat adult patients with advanced renal cell carcinoma (RCC). INLYTA, a kinase inhibitor, is designed to ...
Tags: European Marketing Authorization, INLYTA Oral Therapy